Stock Code: China National Medicines Corporation Ltd(600511) stock abbreviation: China National Medicines Corporation Ltd(600511) Announcement No.: pro 2022015 China National Medicines Corporation Ltd(600511)
Announcement on the general election of the board of directors and the board of supervisors
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
After the term of office of the seventh board of directors and board of supervisors expires, the company will elect the board of directors and board of supervisors in accordance with the relevant provisions of the company law and the articles of association, and plan to form the eighth board of directors and board of supervisors of the company.
The relevant information is hereby announced as follows:
1、 General election of the board of directors
On March 16, 2022, the company held the 37th meeting of the seventh board of directors, deliberated and adopted the proposal on the general election of the board of directors. According to the relevant provisions of the articles of association, the eighth board of directors of the company will be composed of 11 directors, including 7 non independent directors and 4 independent directors.
According to the recommendation of the controlling shareholder, the nomination committee nominated Mr. Jiang Xiuchang, Mr. Liu Yong, Mr. Lian Wanyong, Ms. Li Xiaojuan, Mr. Wen Deyong, Ms. Jiang Xin and Mr. Tian Guotao as candidates for non independent directors of the eighth board of directors of the company (see the annex for resume); Nominate Mr. Yu Xingxi, Mr. Shi Luwen, Mr. Chen Mingyu and Mr. Liu Shen as candidates for independent directors of China National Medicines Corporation Ltd(600511) the eighth board of directors (see Annex for resume).
The above proposal shall be submitted to the 2021 annual general meeting of shareholders of the company for deliberation. The term of office of the eighth board of directors is three years from the date of deliberation and approval by the general meeting of shareholders.
The independent directors expressed relevant independent opinions on this: the nomination procedure of the eighth board of directors of the company complies with the relevant provisions of the company law and the articles of association, the qualifications of each director candidate meet the conditions for serving as a director of a listed company, and there is no situation that he is not allowed to serve as a director of the company as stipulated in the company law, As well as the situation that it is determined as a market prohibited person by the CSRC and the prohibition has not been lifted. Agree to the proposal on the general election of the board of directors of the company.
2、 General election of the board of supervisors
On March 16, 2022, the company held the 27th meeting of the seventh board of supervisors, deliberated and adopted the proposal on the general election of the board of supervisors. According to the relevant provisions of the articles of association, the eighth board of supervisors of the company will be composed of three supervisors. Including 2 non employee representative supervisors and 1 employee representative supervisor.
Now, according to the recommendation of the controlling shareholder, Ms. Liu Jingyun and Mr. Lu Kai are nominated as candidates for the China National Medicines Corporation Ltd(600511) 8th board of supervisors (non employee supervisors) (see the attachment for resume).
The board of supervisors believes that Ms. Liu Jingyun and Mr. Lu Kai are qualified as China National Medicines Corporation Ltd(600511) supervisors, and the recommendation procedure for controlling shareholders is legal and effective.
The above two non employee representative supervisors and one employee representative supervisor elected by the employee congress will jointly form the eighth board of supervisors of the company.
The above proposal shall be submitted to the 2021 annual general meeting of shareholders for deliberation. The term of office of the eighth board of supervisors is 3 years from the date of adoption by the general meeting of shareholders.
It is hereby announced.
China National Medicines Corporation Ltd(600511) March 17, 2022 1. Resume of director candidate 1. Mr. Jiang Xiuchang: born in February 1964, member of the Communist Party of China, bachelor’s degree in financial accounting, senior economist and senior accountant. From July 1986 to March 2002, he worked in Sinopharm group and successively served as deputy director of information department, deputy director of Restructuring Office, deputy director of finance department and deputy manager of drug department. From March 2002 to May 2010, he worked in China National Medicines Corporation Ltd(600511) successively as deputy director of finance department, director of finance department and chief financial officer. From May 2010 to March 2021, he served as the chief financial officer of Sinopharm holdings. From July 2013 to now, he has served as the vice president of Sinopharm holdings, and also served as the chairman and director of several subsidiaries of Sinopharm holdings. He served as the director of China National Medicines Corporation Ltd(600511) from March 2011 to December 2017, served as the chairman of China National Medicines Corporation Ltd(600511) since December 2017, and performed the duties of China National Medicines Corporation Ltd(600511) general manager from January to August 2021. 2. Mr. Liu Yong, born in January 1969, is a member of the Communist Party of China, with a doctorate degree, in charge of pharmacists and licensed pharmacists. Since July 1992, he has successively worked in Shanghai Pharmaceuticals Holding Co.Ltd(601607) station, China Meheco Group Co.Ltd(600056) Group Shanghai company, Shanghai Guoda pharmacy chain Co., Ltd. and Sinopharm holding Shenyang Co., Ltd. Since January 2009, he has served as the senior management of Sinopharm holdings. Now he is the director, President and Deputy Secretary of the Party committee of Sinopharm holdings. He also serves as the director of Sinopharm industrial investment and the chairman and director of several subsidiaries of Sinopharm holdings. From April 2010 to now, he has served as China National Medicines Corporation Ltd(600511) director. 3. Mr. Lian Wanyong, born in November 1970, is a member of the Communist Party of China, with a master’s degree in medicine / Business Administration and deputy chief pharmacist. From July 2005 to January 2018, he worked in Sinopharm group and successively served as deputy director of financial asset management department, director of investment management department and deputy director of policy research office. He served as director of Sinopharm industrial investment from December 2008 to March 2014, and successively served as director and supervisor of Sinopharm holdings from December 2008 to January 2018. From January 2018 to now, he has served as vice president of Sinopharm holdings and chairman and director of several subsidiaries of Sinopharm holdings. From January 2018 to now, he has served as China National Medicines Corporation Ltd(600511) director. 4. Ms. Li Xiaojuan, born in January 1976, is a CPC member with a master’s degree, senior economist, non practicing certified public accountant and asset appraiser. From April 2001 to February 2005, he successively served as the project manager of Beijing Tianhua certified public accountants and the deputy director of the Strategic Cooperation Department of Dongsheng Group Co., Ltd. From February 2005 to August 2010, he successively served as the manager of finance department, director of audit and supervision office and manager of Audit Department of China Meheco Group Co.Ltd(600056) Industry Co., Ltd. 2. From August 2010 to March 2021, he successively served as deputy director of investment management department, deputy director of audit department, director of audit department and director of Finance Department of Sinopharm group. 2. From January 2016 to March 2021, he served as the supervisor of Sinopharm holdings. Since March 021, he has served as the chief financial officer of Sinopharm holdings and also as the chairman and director of several subsidiaries of Sinopharm holdings.
5. Mr. Wen Deyong, born in December 1971, holds a master’s degree in business administration. He joined Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) in May 2002 and is now the senior vice president of Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) and the co president of Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) Industrial Development Co., Ltd. From September 1995 to may 2016, he worked in Chongqing Yaoyou Pharmaceutical Co., Ltd. and Chongqing hesman Pharmaceutical Co., Ltd. Since September 2017, he has served as a director of Sinopharm holdings. At present, he is a director of Sinopharm industrial investment and China National Accord Medicines Corporation Ltd(000028) supervisor. From May 2019 to now, he has served as China National Medicines Corporation Ltd(600511) director. 6. Ms. Jiang Xin, born in March 1970, is a member of the Communist Party of China, Bachelor of science and senior engineer. From August 1994 to August 1997, assistant engineer of Beijing No. 4 pharmaceutical factory. From August 1997 to November 2009, he worked in China Biotechnology Co., Ltd. and successively served as an employee of the asset management department, the chief accountant of the finance department and the deputy manager of the planning and development department. From November 2009 to March 2021, he worked in Sinopharm group and successively served as deputy director of planning and development department, deputy director of strategic planning department, director of strategic planning department, director of strategy and brand management department and deputy director (concurrently) of policy research office. From March 2021 to now, he has served as secretary of China National Medicines Corporation Ltd(600511) Party committee. 7. Mr. Tian Guotao, born in October 1970, is a member of the Communist Party of China, a junior college student and a pharmacist. From August 1989 to June 2008, he worked in the pharmacy department of Beijing Hospital of the Ministry of health, and successively served as pharmacist, deputy director of the drug supply room and Deputy Secretary of the Party branch. From July 2008 to June 2009, he served as the director of the government affairs department of guokong Huahong, from June 2009 to June 2015, as the deputy general manager of guokong Huahong, from July 2015 to December 2015, as the deputy general manager and Party branch secretary of guokong Huahong, and from January 2016 to now, as the general manager and Party branch secretary of guokong Huahong. From August 2021 to now, he has served as China National Medicines Corporation Ltd(600511) Deputy General Manager (presiding over the operation). Since October 2021, he has served as the chairman of Sinopharm holding Beijing Huahong Co., Ltd.
8. Mr. Yu Xingxi: born in 1958, Chinese nationality, Bachelor of economics, master of management, senior accountant title, with Chinese certified public accountant, certified tax agent, enterprise legal adviser, fund practice and other qualifications. At present, he is the Secretary General of Beijing Association of listed companies and concurrently holds the posts of part-time professor of School of economics and management of Beijing Jiaotong University. He once served as the board secretary, press spokesman, finance minister, investment manager, director, chairman, general manager, chief financial officer and general accountant of China Railway Construction Corporation (now China Railway Construction Corporation) and its overall listed a + H listed company China Railway Construction Corporation Limited(601186) and participated in or presided over IPO, private placement, M & A, domestic and foreign convertible bonds A + H listed companies spin off their subsidiaries to overseas listing and other capital operations, creating many firsts. He has in-depth research on financial accounting, investment and financing, capital market and corporate governance. He is one of the members of the “50 people forum on Chinese corporate governance” established on October 31, 2020. He has published more than 80 professional papers, many of which have won awards or been reprinted. Since August 2017, he has opened a column of “happy news and see more” in the magazine of new financial management (monthly), and often writes articles for the magazine of the board of directors and other media. During his tenure as secretary of the board of directors, China Railway Construction Corporation Limited(601186) board of directors was rated as a well functioning board of directors by the state owned assets supervision and Administration Commission of the State Council every year, and won many awards including “excellent board of directors”. Yu Xingxi himself won more than 40 awards in the post of Director Secretary, including five times of new fortune “gold medal Director Secretary” and entered the Director Secretary Hall of fame, two times of new fortune gold medal Director Secretary “top ten capital operation” award, the only sina finance gold medal Director Secretary “lifetime honor Award” and the only “China top 100 Lifetime Achievement Award”, And the “top ten directors and secretaries of China” and other awards of China CFO conference. Since February 2022, he has served as an independent director of Beijing Creative Distribution Automation Co.Ltd(002350) International Human Resources Co., Ltd. (Stock Code: Beijing Career International Co.Ltd(300662) ). 9. Mr. Shi Luwen: born in 1963, Professor, doctoral supervisor. He used to be an expert in the evaluation of the pilot work of basic medical insurance for urban residents under the State Council and an expert of the Advisory Group of experts on deepening the reform of the medical and health system of the Ministry of health. He has successively served as vice president of the school of pharmacy of Beijing Medical University, director of the logistics department, deputy director of the medical department of Peking University and assistant director of the Beijing Health Bureau; He is currently a professor and doctoral supervisor of the Department of pharmaceutical management and clinical pharmacy, School of pharmacy, Peking University, and director of the International Research Center for pharmaceutical management, Peking University. He is also the vice chairman of the pharmaceutical management committee of China Pharmaceutical Association, the standing member of the pharmaceutical management committee of China Hospital Association, the standing director of China Medical Insurance Research Association, the vice chairman of the drug policy committee of China Meheco Group Co.Ltd(600056) innovation promotion association, the vice chairman of the pediatric Professional Committee of China Research Hospital Association and the chairman of the pharmaceutical economics Professional Committee Vice chairman of the special committee of evidence-based pharmacoeconomics of China Association for the promotion of international exchanges in health care, chairman of the professional committee of pharmacoeconomics of Beijing Pharmaceutical Association, and member of the Expert Committee for the evaluation of generic drug quality and efficacy consistency of the State Drug Administration. At the same time, Ren Honghe is an independent non-executive director of Renai Medical Group Co., Ltd. (Hong Kong stock) and China Meheco Group Co.Ltd(600056) (stock code China Meheco Group Co.Ltd(600056) ) is an independent director. 10. Mr. Chen Mingyu, born in 1963 in Hong Kong, China, holds a master’s degree in Business Administration from futenmo University in the United States, and passed five Chinese certified tax agent examinations at one time in 2000 to obtain the practicing qualification certificate of Chinese certified tax agent. He has successively served as the tax partner of Deloitte Touche Tohmatsu, Ernst & young and KPMG enterprise consulting companies and the managing partner of global finance, taxation and M & A services of many large Chinese enterprises. Since August 2017, he has served as the managing partner of De and an (Beijing) Enterprise Consulting Co., Ltd. He has been a visiting professor at Tsinghua University since September 2017, teaching tax management. Acting as an independent director of Fujian Cosunter Pharmaceutical Co.Ltd(300436) (stock code Fujian Cosunter Pharmaceutical Co.Ltd(300436) ) since December 2017. Since December 2020, he has served as an independent director of Beijing Changxin film and television media Co., Ltd. (a non listed company). 11. Mr. Liu Shen, born in December 1975, holds a doctoral degree. Once worked in China Construction Bank Corporation(601939) Shanghai Branch of China and Shanghai Stock Exchange. Now he is the deputy general manager of Shanghai xinfugang Real Estate Development Co., Ltd., and concurrently serves as an independent director of Beijing Shougang Co.Ltd(000959) (stock code Beijing Shougang Co.Ltd(000959) ), an independent director of Shanghai Kangheng environment Co., Ltd. (non listed company), an independent director of Guizhou Guotai Liquor Co., Ltd. (non listed company) Independent director of Shanghai Ziyan Food Co., Ltd. (non listed company). 2、 Resume of non employee representative supervisor candidates
1. Ms. Liu Jingyun was born in October 1976. From May 2003 to October 2003, served as the financial department of Shanghai Chemical Reagent Company of Sinopharm group; Since November 2003, he has worked in Sinopharm holdings, successively serving as deputy director of capital and credit management department, director of capital and credit management department, director of Finance and asset management department and director of capital department. From December 2011 to now, he has served as China National Medicines Corporation Ltd(600511) supervisor. 2. Mr. Lu Kai, born in November 1983, is a member of the Communist Party of China and holds a doctoral degree. He has successively held the posts of commissioner, director, deputy minister and Minister of risk and operation management department. Since July 2020, he has been the Deputy Minister of risk and operation management department of Sinopharm holdings. At present, he is also a director of Sinopharm holding Fujian Co., Ltd.
